Certara, Inc. (NASDAQ:CERT) Receives Average Rating of “Hold” from Analysts

Shares of Certara, Inc. (NASDAQ:CERT) have received an average recommendation of “Hold” from the eight analysts that are covering the firm, Marketbeat.com reports. Six investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $15.92.

Several equities research analysts recently weighed in on CERT shares. Barclays reduced their target price on Certara from $14.00 to $12.00 and set an “equal weight” rating for the company in a report on Thursday, November 7th. Robert W. Baird decreased their price objective on shares of Certara from $18.00 to $13.00 and set a “neutral” rating for the company in a report on Tuesday, November 5th. Finally, UBS Group upgraded shares of Certara from a “neutral” rating to a “buy” rating and set a $16.00 target price on the stock in a report on Friday, September 27th.

Certara Price Performance

NASDAQ CERT opened at $11.21 on Tuesday. The company has a quick ratio of 2.86, a current ratio of 2.86 and a debt-to-equity ratio of 0.28. The stock has a market capitalization of $1.80 billion, a PE ratio of -56.05, a price-to-earnings-growth ratio of 5.86 and a beta of 1.53. Certara has a 12-month low of $9.41 and a 12-month high of $19.87. The company has a 50 day moving average price of $10.76 and a two-hundred day moving average price of $12.09.

Certara (NASDAQ:CERT) last released its quarterly earnings data on Wednesday, November 6th. The company reported $0.13 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.11 by $0.02. The business had revenue of $94.80 million during the quarter, compared to analyst estimates of $95.51 million. Certara had a negative net margin of 8.34% and a positive return on equity of 3.43%. Certara’s quarterly revenue was up 10.7% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.06 EPS. As a group, equities analysts predict that Certara will post 0.28 earnings per share for the current fiscal year.

Insider Activity at Certara

In related news, insider Patrick F. Smith sold 5,409 shares of the company’s stock in a transaction on Monday, October 7th. The stock was sold at an average price of $11.03, for a total value of $59,661.27. Following the completion of the transaction, the insider now directly owns 50,091 shares in the company, valued at approximately $552,503.73. This represents a 9.75 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 2.39% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Certara

Several institutional investors and hedge funds have recently bought and sold shares of the business. The Manufacturers Life Insurance Company boosted its position in shares of Certara by 4.5% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 22,871 shares of the company’s stock valued at $317,000 after acquiring an additional 975 shares in the last quarter. Nicolet Advisory Services LLC boosted its holdings in Certara by 6.6% during the third quarter. Nicolet Advisory Services LLC now owns 24,831 shares of the company’s stock valued at $273,000 after purchasing an additional 1,531 shares in the last quarter. KBC Group NV grew its stake in shares of Certara by 48.2% in the 3rd quarter. KBC Group NV now owns 4,873 shares of the company’s stock valued at $57,000 after purchasing an additional 1,584 shares during the period. Blue Trust Inc. raised its holdings in shares of Certara by 112.3% in the 3rd quarter. Blue Trust Inc. now owns 3,925 shares of the company’s stock worth $46,000 after buying an additional 2,076 shares in the last quarter. Finally, Everence Capital Management Inc. lifted its position in shares of Certara by 21.0% during the 3rd quarter. Everence Capital Management Inc. now owns 14,910 shares of the company’s stock worth $175,000 after buying an additional 2,590 shares during the period. Institutional investors own 73.96% of the company’s stock.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.